Spyre Therapeutics (SYRE) Other Non-Current Assets (2015 - 2025)
Spyre Therapeutics posted quarterly Other Non-Current Assets of $10000.0 for Q1 2025, little changed year-on-year from $10000.0 in Q1 2024, and little changed on a QoQ basis from $10000.0 in Q4 2024.
Spyre Therapeutics (SYRE) has 11 years of Other Non-Current Assets data on file, last reported at $10000.0 in Q1 2025.
- For the quarter ending Q1 2025, Other Non-Current Assets changed 0.0% year-over-year to $10000.0; the trailing twelve-month figure through Mar 2025 stood at $10000.0 (changed 0.0% YoY), and the FY2024 full-year result was $10000.0, down 96.89% from the prior year.
- Other Non-Current Assets for Q1 2025 stood at $10000.0, roughly flat from $10000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.8 million in Q2 2021 and bottomed at $10000.0 in Q1 2024.
- The 5-year median for Other Non-Current Assets is $1.3 million (2023), against an average of $1.0 million.
- The widest annual swing landed in 2021, when Other Non-Current Assets surged 1906.52%; it then plunged 99.24% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $1.8 million in 2021, then fell by 15.51% to $1.6 million in 2022, then slumped by 79.27% to $322000.0 in 2023, then sank by 96.89% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $10000.0 (Q1 2025), $10000.0 (Q4 2024), and $10000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 322,000.00 |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 1.55 Mn |
| Sep 30, 2022 | 1.53 Mn |
| Jun 30, 2022 | 1.80 Mn |
| Mar 31, 2022 | 800,000.00 |
| Dec 31, 2021 | 1.84 Mn |
| Sep 30, 2021 | 897,000.00 |
| Jun 30, 2021 | 1.85 Mn |
| Mar 31, 2021 | 1.85 Mn |
| Dec 31, 2020 | 115,000.00 |
| Sep 30, 2020 | 1.50 Mn |
| Jun 30, 2020 | 92,000.00 |
| Mar 31, 2020 | 1.50 Mn |
| Dec 31, 2019 | 67,000.00 |
| Sep 30, 2019 | 114,000.00 |
| Jun 30, 2019 | 120,000.00 |
| Mar 31, 2019 | 749,000.00 |
| Dec 31, 2018 | 50,000.00 |
| Sep 30, 2018 | 49,000.00 |
| Jun 30, 2018 | 49,000.00 |
| Mar 31, 2018 | 133,000.00 |
| Dec 31, 2017 | 232,000.00 |
| Sep 30, 2017 | 139,000.00 |
| Jun 30, 2017 | 139,000.00 |
| Mar 31, 2017 | 140,000.00 |
| Dec 31, 2016 | 40,000.00 |
| Sep 30, 2016 | 40,000.00 |
| Jun 30, 2016 | 155,000.00 |
| Mar 31, 2016 | 80,000.00 |
| Dec 31, 2015 | 20,000.00 |